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We report a case of a successful mobilization and harvest of the peripheral blood stem cells (PBSCs) in imatinib-pretreated and
nilotinib treated 52-year-old woman diagnosed with Philadelphia chromosome-positive and BCR-ABL (b2a2) positive chronic
phase CML in 2/2002. She failed interferon-alfa and imatinib treatment. She achieved her ﬁrst complete molecular remission after
16 months of nilotinib treatment and later on was mobilized with ﬁlgrastim at a dose of 10ug/kg/day applied subcutaneously once
daily. The total number of 2.98 × 106 CD34+cells/kg was harvested on the fourth day of the mobilization. The autologous graft
of the stem cells was cryopreserved and tested for the residual disease: the FISH revealed negative results and the RT-PCR was
positive (BCR-ABL/ABL ratio 0,0017 in RQ-PCR). To our knowledge, this is the ﬁrst report of successful PBSC harvest in a patient
signiﬁcantly pretreated with imatinib and nilotinib.
TheLetter
The majority of patients diagnosed with chronic phase
chronic myeloid leukemia (CML) can expect to have durable
responses (88% OS at 6 years) with good quality of life on
imatinib treatment [1]. Allogeneic stem cells transplantation
(SCT) is no longer considered as the ﬁrst line treatment
in such patients and since 1999 there was a considerable
reductioninthenumbersofthesetransplantsreportedtothe
European Group for Blood and Marrow Transplantation—
EBMT [2]. Autologous SCT might decrease the disease pro-
gression, oﬀer valuable prolongation of survival for selected
groups of patients, and can restore susceptibility to imatinib
[3]. According to EBMT recommendations, however, this
treatment strategy remains considered as developmental in
chronic and accelerated CML phase [3, 4]. The number
of autologous SCT for CML has been very low recently
and only 6 cases were reported to the EBMT in 2007 [5].
On the other hand, clinical trials showed feasibility and
eﬃcacy of collection and storage of peripheral blood stem
cells (PBSCs) from imatinib-treated patients in complete
cytogenetic remission [6, 7]. However, experience with
harvestingPBSCinnilotinib-treatedCMLpatientsislacking.
Nilotinib (AMN107,Tasigna-Novartis),asecondgenera-
tion tyrosine-kinase inhibitor and aminopyrimidine deriva-
tive of imatinib with activity against Arg, Kit, and platelet-
derived growth factor receptor (PDGFR), but not Src-
family kinases, is 10 to 50 times more potent than imatinib
in inhibiting the proliferation and autophosphorylation of
wild-type BCR-ABL cell lines and most of the BCR-ABL
mutants, except the T315I mutant [8]. Predominant eﬀect
of nilotinib is antiproliferative rather than proapoptotic
and does not induce apoptosis in primitive CD34+ CML
cells; whereas those more mature are beginning to undergo
apoptosis [9]. In chronic phase CML patients, resistant or
intolerant to imatinib, nilotinib leads to 44% complete cyto-
genetic remissions (CCyR) that are durable with estimated 2
y e a r sO S8 8 %[ 10].2 Journal of Oncology
Here we report a case of successful mobilization and
harvest of PBSC in imatinib pretreated and nilotinib
treated 52-year-old woman with no related stem cells
donor available and reluctant to undergo an alternative
donor search. The patient was diagnosed with Philadel-
phia chromosome-positive and BCR-ABL (b2a2) positive
chronic phase CML, presenting as intermediate prognostic
group both sec. Sokal and Hasford, in 2/2002. Due to
interferon-alfa resistance, imatinib 400mg/day was started
in 7/2002. The ﬁrst CCyR was achieved twenty months
later. Unfortunately, the cytogenetic relapse occurred in
3/2006. Due to further disease progression, despite the
imatinib 600mg/day escalation, nilotinib was started 400mg
twicedaily within the CAMN107A Novartis Pharmaceuticals
open-label ENACT trial in 12/2006. The second CyCR was
achieved after 6 months (in 6/2007) and the ﬁrst complete
molecular remission (CMoR) after 16 months (in 4/2008)
of the nilotinib treatment. In 2/2009, while being still in
her ﬁrst CMoR, the patient agreed on the autologous PBSC
mobilization.
The patient was mobilized with ﬁlgrastim (Neupogen,
Amgen, USA) at a dose of 10ug/kg/day applied subcu-
taneously once daily for four days. The CML treatment
was not interrupted and nilotinib was administered to the
patient during the mobilization and harvest. The baseline
and the apheresis day (the fourth day of the mobilization)
values of the leucocytes, hemoglobin, and platelets were: 7,0
and 44,3 × 109/L, 140 and 134g/L, 296 and 320 × 109/L,
respectively. The CD34+ count in peripheral blood at the
day of the apheresis reached 62,0cells/µL (the enumeration
performed by the ISHAGE-based protocol on the Coulter
XL ﬂow cytometer). The PBSC apheresis was performed
by means of continuous-ﬂow blood cell separator (COBE
Spectra, Caridian BCT, USA) via dialysis catheter inserted
into femoral vein. Acid citrated dextrose (ACD-A) was
used as the anticoagulant. The processed blood volume
ranged between two and three times of the patient’s total
blood volume (15 litres). The apheresis product contained
2,98 × 106 CD34+cell/kg patient’s weight was subjected
to controlled rate freezing (IceCube, SY-LAB, Austria) and
stored in liquid nitrogen under standard conditions. The
product was also tested for the residual disease: the FISH
revealed negative results, the RT-PCR was positive (BCR-
ABL/ABL ratio 0,0017 in RQ-PCR).
The mobilization and harvest complications included
elevated body temperature up to 37,5 degrees centigrade,
moderate musculoskeletal pains, headache and mild citrate
toxicity with paresthesias. In 10/2009, the patient keeps on
nilotinib treatment 400mg twice daily (35 months duration)
and remains in CMoR with good quality of life for almost
eight years since the diagnose.
As for the methodology of the laboratory testing, the
BCR-ABL transcripts were measured in bone marrow sam-
ples using end-point nested real-time PCR (RT-PCR) with
minimum sensitivity of 1 : 1000000 and real-time quantita-
tive PCR (RQ-PCR) for BCR-ABL and ABL genes by means
of FusionQuant
R Kit (Ipsogen, France) on Light Cycler 1.2
platform with minimum sensitivity of 1 : 100000. Complete
molecular remission (CMoR) was deﬁned as no detectable
transcriptsbothinRTandRQ-PCR.TheFluorescenceinsitu
hybridization (FISH) analysis was performed to detect BCR-
ABLfusiongeneusingtheVysisLSIBCR/ABLESDualColor
Translocation Probe Set (Abbott Molecular Inc., USA) with
the sensitivity of 1 : 200.
To our knowledge, this is the ﬁrst report of successful
PBSC harvest in a patient signiﬁcantly pretreated with
imatinib and nilotinib. The procedure was feasible with
only mild and expected side eﬀects. Respecting the mode
of nilotinib action and concentration of CD34+ cells within
the autologous graft, presence of BCR-ABL positive cells is
likely to be anticipated even in a patient in CMoR. In the
Bhatia et al. [7] cohort of imatinib patients, only 8% of
134 autologous PBSC collections were PCR negative. Given
the feasibility of PBSC collection in imatinib and nilotinib-
treated patients, with the individual role of the autologous
SCT in CML treatment, the PBSC collections should be
considered in otherwise transplantable patients without
available and suitable donor of allogeneic hematopoietic
stem cells.
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